← Eichor
Condition: Prostate Cancer Stage Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Prostate Cancer Stage

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of
NA · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06995053A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Angela Y. Jia, MD PhD · NCT06574880A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or M
Phase 1/Phase 2 · 4 location(s) · Genentech, Inc. · NCT07567846A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patien
Phase 2/Phase 3 · 2 location(s) · Shanghai Jiao Tong University School of Medicine · NCT03258320SRT Versus SRT+ADT in Prostate Cancer
Phase 3 · 1 location(s) · Marco Lorenzo Bonu · NCT05019846Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recu
Phase 2 · 1 location(s) · Mayo Clinic · NCT07073794Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
Phase 2 · 1 location(s) · Emory University · NCT06865768High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Phase N/A · 1 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT06982469Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06330805CART-PSMA Cells for Advanced Prostate Cancer
Phase 1 · 1 location(s) · Nova Therapeutics LLC · NCT05656573Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05616650The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
NA · 1 location(s) · NHS Lothian · NCT06117059Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Phase 3 · 1 location(s) · HTA Co., Ltd. · NCT06754085Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
Phase 2 · 1 location(s) · Maria Sklodowska-Curie National Research Institute of Oncolo · NCT06201078Binaural Sound for Remimazolam Maintenance
NA · 1 location(s) · Gangnam Severance Hospital · NCT06497283Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Phase 4 · 54 location(s) · Novartis Pharmaceuticals · NCT05803941A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Phase 1/Phase 2 · 3 location(s) · SpectraCure AB · NCT06807359A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastati
Phase 1/Phase 2 · 1 location(s) · CuraCell TX AB · NCT07255664HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Pros
Phase 2 · 15 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT07717268Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06200103A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic H
Phase 2 · 67 location(s) · Novartis Pharmaceuticals · NCT06991556
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.